JP2022526670A5 - - Google Patents

Info

Publication number
JP2022526670A5
JP2022526670A5 JP2021560111A JP2021560111A JP2022526670A5 JP 2022526670 A5 JP2022526670 A5 JP 2022526670A5 JP 2021560111 A JP2021560111 A JP 2021560111A JP 2021560111 A JP2021560111 A JP 2021560111A JP 2022526670 A5 JP2022526670 A5 JP 2022526670A5
Authority
JP
Japan
Prior art keywords
editing system
gene editing
cells
polynucleotide
nucleotide sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021560111A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022526670A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/027690 external-priority patent/WO2020210640A1/en
Publication of JP2022526670A publication Critical patent/JP2022526670A/ja
Publication of JP2022526670A5 publication Critical patent/JP2022526670A5/ja
Priority to JP2025068218A priority Critical patent/JP2025118676A/ja
Pending legal-status Critical Current

Links

JP2021560111A 2019-04-12 2020-04-10 Ｓｃｎ９ａまたはｓｃｎ１０ａ遺伝子を改変するための遺伝子編集システム及びそれらの使用方法 Pending JP2022526670A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025068218A JP2025118676A (ja) 2019-04-12 2025-04-17 Ｓｃｎ９ａまたはｓｃｎ１０ａ遺伝子を改変するための遺伝子編集システム及びそれらの使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962833523P 2019-04-12 2019-04-12
US62/833,523 2019-04-12
PCT/US2020/027690 WO2020210640A1 (en) 2019-04-12 2020-04-10 Gene-editing systems for modifying a scn9a or scn10a gene and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025068218A Division JP2025118676A (ja) 2019-04-12 2025-04-17 Ｓｃｎ９ａまたはｓｃｎ１０ａ遺伝子を改変するための遺伝子編集システム及びそれらの使用方法

Publications (2)

Publication Number Publication Date
JP2022526670A JP2022526670A (ja) 2022-05-25
JP2022526670A5 true JP2022526670A5 (enExample) 2023-04-18

Family

ID=70416602

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021560111A Pending JP2022526670A (ja) 2019-04-12 2020-04-10 Ｓｃｎ９ａまたはｓｃｎ１０ａ遺伝子を改変するための遺伝子編集システム及びそれらの使用方法
JP2025068218A Pending JP2025118676A (ja) 2019-04-12 2025-04-17 Ｓｃｎ９ａまたはｓｃｎ１０ａ遺伝子を改変するための遺伝子編集システム及びそれらの使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025068218A Pending JP2025118676A (ja) 2019-04-12 2025-04-17 Ｓｃｎ９ａまたはｓｃｎ１０ａ遺伝子を改変するための遺伝子編集システム及びそれらの使用方法

Country Status (15)

Country Link
US (1) US20200354741A1 (enExample)
EP (1) EP3953460A1 (enExample)
JP (2) JP2022526670A (enExample)
KR (2) KR20210151110A (enExample)
CN (2) CN119286934A (enExample)
AU (1) AU2020272031B2 (enExample)
BR (1) BR112021020406A2 (enExample)
CA (1) CA3136700A1 (enExample)
CO (1) CO2021014015A2 (enExample)
EA (1) EA202192806A1 (enExample)
IL (2) IL328663A (enExample)
JO (1) JOP20210276A1 (enExample)
MX (3) MX2021012493A (enExample)
SG (1) SG11202111270SA (enExample)
WO (1) WO2020210640A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240366680A1 (en) * 2021-08-16 2024-11-07 Editas Medicine, Inc. Treatment of pain
EP4731643A2 (en) * 2023-06-26 2026-04-29 Navega Therapeutics, Inc. Compositions and methods for reducing pain and inflammation through epigenetic modulation
AU2025207849A1 (en) * 2024-01-11 2026-07-16 Regeneron Pharmaceuticals, Inc. Viral particles retargeted to nervous system tissues
WO2025153066A1 (zh) * 2024-01-19 2025-07-24 云合智药（苏州）生物科技有限公司 用于抑制钠电压门控通道α亚基10(SCN10A)基因表达的核酸及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201418713D0 (en) * 2014-10-21 2014-12-03 Kymab Ltd Bindings Proteins
WO2016205759A1 (en) * 2015-06-18 2016-12-22 The Broad Institute Inc. Engineering and optimization of systems, methods, enzymes and guide scaffolds of cas9 orthologs and variants for sequence manipulation
EP3481857B1 (en) * 2016-07-06 2026-02-11 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of pain related disorders
EP4650364A3 (en) * 2016-07-06 2026-01-21 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of pain related disorders
WO2018165504A1 (en) * 2017-03-09 2018-09-13 President And Fellows Of Harvard College Suppression of pain by gene editing

Similar Documents

Publication Publication Date Title
EP3684924B1 (en) Non-integrating dna vectors for the genetic modification of cells
JP7197363B2 (ja) ヌクレアーゼを使用するヒト神経幹細胞のゲノム編集
DE69429260T3 (de) Adenovirale vektoren tierischen ursprungs und ihre verwendung bei der gentherapie
JP2022546608A5 (enExample)
JP2022520081A5 (enExample)
JP2021521855A5 (enExample)
JP2022545950A5 (enExample)
JP2022519882A5 (enExample)
AU2012358384A1 (en) Methods of increasing the viability or longevity of an organ or organ explant
JP2020518268A5 (enExample)
CN114599403A (zh) 通过基于crispr/cas9的转录激活物获得的骨骼肌成肌细胞祖细胞谱系的特化
JP2021514207A5 (enExample)
JP2024546841A5 (enExample)
US20220098254A1 (en) NEUROD1 and DLX2 VECTOR
TW202235622A (zh) 包裹rna之指環病毒(anellovirus)蛋白殼之活體外組裝
Yuan et al. A simple and efficient approach to construct mutant vaccinia virus vectors
WO2022072309A1 (en) Ascl1 vector
Lal et al. Curative Therapy of Sickle Cell Disease Using Gene Editing Technologies
CN115487315B (zh) 治疗亨廷顿病的药物
US20220290157A1 (en) Compositions and methods for treating amyotrophic lateral sclerosis
WO2022072310A1 (en) Dlx2 vector
HK40093193A (en) Non-integrating dna vectors for the genetic modification of cells
CN116670160A (zh) Dlx2载体
CN116761812A (zh) Neurod1和dlx2载体
JP2025506403A5 (enExample)